Mohs R C, Davis B M, Greenwald B S, Mathé A A, Johns C A, Horvath T B, Davis K L
J Am Geriatr Soc. 1985 Nov;33(11):749-57. doi: 10.1111/j.1532-5415.1985.tb04185.x.
Two studies investigated the ability of physostigmine, given both intravenously and orally, to reduce symptoms of Alzheimer's disease. Intravenous physostigmine significantly and reliably enhanced memory in 13 of 16 patients tested, but the dose producing the improvement varied among patients. Oral physostigmine decreased overall symptom severity in a reliable way in seven of 12 patients tested. The extent of improvement was correlated with the increase in mean cortisol secretion produced by physostigmine, suggesting that the drug improved behavior and cognition only to the extent that it had a specific central cholinomimetic effect. There was no significant association between response to physostigmine and results of a dexamethasone suppression test and physostigmine had no effect on growth hormone secretion.
两项研究调查了静脉注射和口服毒扁豆碱减轻阿尔茨海默病症状的能力。在16名接受测试的患者中，有13名患者静脉注射毒扁豆碱后，记忆力显著且可靠地得到增强，但产生改善效果的剂量在患者之间存在差异。在12名接受测试的患者中，有7名患者口服毒扁豆碱后总体症状严重程度可靠地降低。改善程度与毒扁豆碱引起的平均皮质醇分泌增加相关，这表明该药物仅在具有特定的中枢拟胆碱作用的程度上改善行为和认知。对毒扁豆碱的反应与地塞米松抑制试验结果之间无显著关联，且毒扁豆碱对生长激素分泌无影响。
